Latest Articles
DUO-E Phase III Trial: Durvalumab Plus Olaparib Maintenance in pMMR Endometrial Cancer - Oncodaily
DUO-E Phase III Trial: Durvalumab Plus Olaparib Maintenance in pMMR Endometrial Cancer Oncodaily
Published: Feb. 23, 2026, 6:45 a.m.
Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair.
Endometriosis is a chronic, hormone-dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, …
Published: Feb. 18, 2026, midnight
Olaparib Maintenance in Advanced Endometrial Cancer Trial - BIOENGINEER.ORG
Olaparib Maintenance in Advanced Endometrial Cancer Trial BIOENGINEER.ORG
Published: Aug. 26, 2025, 3:07 p.m.
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Nature
Published: Aug. 26, 2025, 11:43 a.m.
AstraZeneca’s New Study on Durvalumab and Olaparib in Endometrial Cancer: Market Implications - TipRanks
AstraZeneca’s New Study on Durvalumab and Olaparib in Endometrial Cancer: Market Implications TipRanks
Published: July 2, 2025, 5:03 p.m.
Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets - The ASCO Post
Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets The ASCO Post
Published: March 24, 2025, 2:03 p.m.
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups - OBR Oncology
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups OBR Oncology
Published: March 18, 2025, 10:24 a.m.
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups - Oncology News Central
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups Oncology News Central
Published: March 18, 2025, 10:24 a.m.
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups - oncologynewscentral.com
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups oncologynewscentral.com
Published: March 18, 2025, 10:24 a.m.
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer - OncLive
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer OncLive
Published: March 15, 2025, 4:52 p.m.
Link copied to clipboard!